176 related articles for article (PubMed ID: 17178265)
1. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.
Kim KA; Park PW; Lee OJ; Choi SH; Min BH; Shin KH; Chun BG; Shin JG; Park JY
Clin Pharmacol Ther; 2006 Dec; 80(6):646-56. PubMed ID: 17178265
[TBL] [Abstract][Full Text] [Related]
2. Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects.
Kim KA; Park PW; Park JY
Chirality; 2009 May; 21(5):485-91. PubMed ID: 18752284
[TBL] [Abstract][Full Text] [Related]
3. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.
Kim KA; Park PW; Lee OJ; Kang DK; Park JY
J Clin Pharmacol; 2007 Jan; 47(1):87-93. PubMed ID: 17192506
[TBL] [Abstract][Full Text] [Related]
4. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects.
Kim KA; Park PW; Park JY
Br J Clin Pharmacol; 2007 Jan; 63(1):53-8. PubMed ID: 16869811
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects.
Jin Y; Wang YH; Miao J; Li L; Kovacs RJ; Marunde R; Hamman MA; Philips S; Hilligoss J; Hall SD
Clin Pharmacol Ther; 2007 Nov; 82(5):579-85. PubMed ID: 17443134
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
Kirchheiner J; Thomas S; Bauer S; Tomalik-Scharte D; Hering U; Doroshyenko O; Jetter A; Stehle S; Tsahuridu M; Meineke I; Brockmöller J; Fuhr U
Clin Pharmacol Ther; 2006 Dec; 80(6):657-67. PubMed ID: 17178266
[TBL] [Abstract][Full Text] [Related]
7. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
Tada H; Tsuchiya N; Satoh S; Kagaya H; Li Z; Sato K; Miura M; Suzuki T; Kato T; Habuchi T
Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
[TBL] [Abstract][Full Text] [Related]
9. No association of the CYP3A5*1 allele with blood pressure and left ventricular mass and geometry: the KORA/MONICA Augsburg echocardiographic substudy.
Lieb W; Bolbrinker J; Döring A; Hense HW; Erdmann J; Schunkert H; Kreutz R
Clin Sci (Lond); 2006 Dec; 111(6):365-72. PubMed ID: 16822233
[TBL] [Abstract][Full Text] [Related]
10. CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir.
Josephson F; Allqvist A; Janabi M; Sayi J; Aklillu E; Jande M; Mahindi M; Burhenne J; Bottiger Y; Gustafsson LL; Haefeli WE; Bertilsson L
Clin Pharmacol Ther; 2007 May; 81(5):708-12. PubMed ID: 17329995
[TBL] [Abstract][Full Text] [Related]
11. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
Niemi M; Leathart JB; Neuvonen M; Backman JT; Daly AK; Neuvonen PJ
Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525
[TBL] [Abstract][Full Text] [Related]
12. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.
Zhao Y; Song M; Guan D; Bi S; Meng J; Li Q; Wang W
Transplant Proc; 2005; 37(1):178-81. PubMed ID: 15808586
[TBL] [Abstract][Full Text] [Related]
14. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
Thervet E; Anglicheau D; King B; Schlageter MH; Cassinat B; Beaune P; Legendre C; Daly AK
Transplantation; 2003 Oct; 76(8):1233-5. PubMed ID: 14578760
[TBL] [Abstract][Full Text] [Related]
15. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
[TBL] [Abstract][Full Text] [Related]
16. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
17. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.
Wong M; Balleine RL; Collins M; Liddle C; Clarke CL; Gurney H
Clin Pharmacol Ther; 2004 Jun; 75(6):529-38. PubMed ID: 15179407
[TBL] [Abstract][Full Text] [Related]
18. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt J; Danhof M; de Fijter JW; Guchelaar HJ
Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
20. Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers.
Kim KA; Joo HJ; Lee HM; Park JY
Pharmacogenet Genomics; 2014 Jan; 24(1):35-42. PubMed ID: 24240480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
